Development of Halobetasol-loaded nanostructured lipid carrier for dermal administration: Optimization, physicochemical and biopharmaceutical behavior, and therapeutic efficacy

Publication date: Available online 4 June 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Paulina Carvajal-Vidal, María-José Fábrega, Marta Espina, Ana Cristina Calpena, M. Luisa GarcíaAbstractHalobetasol propionate (HB) is considered a super potent drug in the group of topical corticosteroids. HB has anti-inflammatory activity, vasoconstriction properties, and due to its high skin penetration, it can cause systemic side effects. To improve its characteristics, enhance topical effectiveness and reduce penetration to systemic circulation, a study to optimize and characterize a HB-loaded lipid nanocarrier (HB-NLC) has been made by high-pressure homogenization method. The formulation is composed by HB, surfactant, glyceryl distearate and capric glycerides. The optimized HB-NLC containing 0.01% of HB and 3% of total lipid shows an average size below 200 nm with a polydispersity index <0.2 and an encapsulation efficiency>90%. The in vitro and in vivo tests indicate that the HB-NLC is not toxic, is well tolerated and has an anti-inflammatory effect because they decrease the production of Interleukins in keratinocytes and monocytes. HB-NLC is considered an alternative treatment for skin inflammatory disorders.Graphical AbstractIn the present study, Halobetasol propionate loaded nanostructured lipid carrier were developed for the treatment of inflammatory skin diseases by high-pressure homogenization method. The results, showed physicochemical an...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research